Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
14.77
-0.07 (-0.47%)
At close: Jun 5, 2026, 4:00 PM EDT
14.78
+0.01 (0.07%)
After-hours: Jun 5, 2026, 7:57 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
11.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Ascendis Pharma | 998.25M |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
SMMT News
- 1 day ago - The Era of the One-Size-Fits-All Cancer Drug Is Ending - WSJ
- 3 days ago - Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference - Business Wire
- 6 days ago - An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed. - Market Watch
- 6 days ago - Summit Therapeutics Transcript: Status update - Transcripts
- 6 days ago - Summit Therapeutics Press release: Status update - Filings
- 6 days ago - Summit Therapeutics Slides: Status update - Filings
- 6 days ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters
- 7 days ago - Summit Therapeutics announces OS results from Phase 3 HARMONi-6 trial - TheFly